Imidazo[1,2-a]pyrazines

Claim 1

A compound represented by the formulas: ##STR40## the 5,6,7,8-tetrahydro, 2,3-dihydro and perhydro derivatives thereof, and the pharmaceutically acceptable salts thereof, wherein: U represents ##STR41## R 2 and R 3 each independently represent hydrogen, lower alkyl, trifluoromethyl, B--CF 3 , Ar, B--Ar, halogen, B--halogen --OR 7 , B--OR 8 , B--SR 6 , --S(O) n --R 7 , S(O) n -- lower alkyl, (wherein n is zero, one or two), ##STR42## or a straight- or branched-chain alkenyl or alkynyl group having 2 to 6 carbon atoms and aryl-substituted derivatives thereof, or taken together are a cyclic alkyl of 3 to 6 bridging carbon atoms; X represents hydrogen, lower alkyl, halogen, hydroxy, lower alkoxy, trifluoromethyl, --NO 2 , --CN, ##STR43## wherein n is zero, one or two with the proviso that when R 1 represents ##STR44## n represents two; Z represents --O--, --S--, --SO--, --SO 2 --, --NR 6 --, or a bond connecting T to the 5-, 6- or 8-position of the imidazo [1,2-a]pyrazine nucleus; B represents a straight- or branched-chain lower alkylene moiety; T represents a straight- or branched-chain lower alkylene moiety and; (a) when Z is a bond connecting T and the imidazo[1,2-a]pyrazine nucleus, T represents the --OR 7 derivatives of said imidazo[1,2-a]pyrazine, or the α(β)- or β(γ)-unsaturated derivatives of said imidazo[1,2-a]pyrazine, or (b) when Z is --O--, T also represents the allylene derivatives of said imidazo[1,2-a]pyrazine; m is zero to 10 with the proviso that when W is Ar, m is not zero and the number of bridging carbons between Z and W is no greater than 5; W represents hydrogen when T is allylene; or Ar, wherein Ar represents phenyl, 2-, 3- or 4- pyridyl, 2- or 3-thienyl, 2- or 4- imidazolyl, 2-, 3-, 4- or 5- furanyl or X'-, Y'- and Z'- substituted phenyl wherein each of X', Y' and Z' independently is as hereinabove defined for X; and when m is 1 to 3, W represents alkenyl, alkynyl, Z 1 R 6 or Z 1 COR 6 wherein Z 1 is O, S, SO, SO 2 or NR 6 ; Y represents --O--, --S--, --SO--, --SO 2 -- or --NR 6 --; where in the above definitions: R 1 represents Ar, lower alkyl, ##STR45## or or Ar-loweralkyl; R 4 and R 5 each independently represents hydrogen, lower alkyl, Ar, Ar-lower alkyl, lower alkoxy lower alkyl, trifluoromethyl lower alkyl, or when taken together with the nitrogen atoms to which they are attached represents a 4- to 7-membered cyclic amino or a morpholino group; R 6 represents hydrogen, C 1 - to C 12 -alkyl, aryl or an arylalkyl group having up to 12 carbon atoms: R 7 , R 7 ' and R 7 " each independently represents hydrogen or loweralkyl; R 8 represents hydrogen, lower alkyl, lower alkoxy lower alkyl, trifluoromethyl lower alkyl, Ar-lower alkyl, or Ar; R 9 represents ##STR46## R 10 represents M, alkali metal or lower alkyl; R 11 and R 12 each independently represents hydrogen or lower alkyl or together represents oxygen; R 13 and R 14 each independently represents hydrogen, alkyl, aryl, or together represents Y; R 15 and R 16 each independently represents hydrogen, alkyl, aryl, or together represent --O-- or --S--, provided that when R 13 and R 14 together represent --O-- or --S--, R 15 and R 16 do not represent --O-- or --S--; p and q are each independently 0, 1 or 2 provided that when one of p and q is zero, the other is not zero.

Claim 19

A method for the treatment of the symptoms of peptic ulcer disease in mammals which comprises administering to a mammal having peptic ulcer disease, a therapeutically effective amount of a compound of claims 6, 7, 8, 9, 10 or 11.